RUNX1 and acute myeloid leukemia: For the majority of CpGs, only a mild gain in methylation in RUNX1-mutated AML patients was observed (Figure 1A, Supplementary Figure S1A, average Δmeth = 0.06); conversely, for the differentially methylated CpG in close proximity to RUNX1 TFBS, the gain in DNA methylation was significantly higher (Figure 1A, Supplementary Figure S1A, average Δmeth = 0.18).